Biomarin Pharmaceutical Stock Today
| BMRN Stock | USD 90.07 0.40 0.44% |
Performance0 of 100
| Odds Of DistressLess than 3
|
Biomarin Pharmaceutical is selling at 90.07 as of the 19th of April 2024; that is -0.44 percent decrease since the beginning of the trading day. The stock's open price was 90.47. Biomarin Pharmaceutical has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Biomarin Pharmaceutical are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 20th of March 2024 and ending today, the 19th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 23rd of July 1999 | Category Healthcare | Classification Health Care |
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The company was incorporated in 1996 and is headquartered in San Rafael, California. Biomarin Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 189.78 M outstanding shares of which 3.06 M shares are currently shorted by private and institutional investors with about 2.39 trading days to cover. More on Biomarin Pharmaceutical
Moving against Biomarin Stock
| 0.77 | MRSN | Mersana Therapeutics Downward Rally | PairCorr |
| 0.73 | EOLS | Evolus Inc Financial Report 14th of May 2024 | PairCorr |
| 0.62 | INZY | Inozyme PharmaInc Financial Report 14th of May 2024 | PairCorr |
| 0.58 | JSPRW | Jasper Therapeutics | PairCorr |
| 0.53 | IOVA | Iovance Biotherapeutics Financial Report 14th of May 2024 | PairCorr |
| 0.45 | EWTX | Edgewise Therapeutics Financial Report 9th of May 2024 | PairCorr |
| 0.45 | IMMP | Immutep Ltd ADR | PairCorr |
Biomarin Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Biomarin Pharmaceutical's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Biomarin Pharmaceutical or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary, Biomarin Pharmaceutical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Biomarin Pharmaceutical's managers, analysts, and investors.
Environment Score | Governance Score | Social Score |
| CEO President | Alexander Hardy | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, ARCA Biotechnology, Dow Jones Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Excise Tax Activities | Animal Testing | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Biomarin Pharmaceutical report their recommendations after researching Biomarin Pharmaceutical's financial statements, talking to executives and customers, or listening in on Biomarin Pharmaceutical's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Biomarin Pharmaceutical. The Biomarin consensus assessment is calculated by taking the average forecast from all of the analysts covering Biomarin Pharmaceutical. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the analysis of Biomarin Pharmaceutical's profitability, liquidity, and operating efficiency, Biomarin Pharmaceutical is doing better financially then in previous quarter. It has a moderate odds of reporting better financial numbers in May. Financial strength of Biomarin Pharmaceutical is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Biomarin Pharmaceutical's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Biomarin Pharmaceutical's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. Biomarin Pharmaceutical's bond ratings measure its overall creditworthiness, which in many ways corresponds to the cost of borrowing for an issuer. These ratings assign a letter grade to all of Biomarin Pharmaceutical's outstanding corporate bonds that indicate their credit quality. We use reports published by private self-sufficient rating services such as Standard & Poor's or Fitch Ratings Inc. to evaluate a bond issuer's financial strength or its ability to pay a bond's principal and interest. Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Biomarin Pharmaceutical's financial leverage. It provides some insight into what part of Biomarin Pharmaceutical's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Biomarin Pharmaceutical (BMRN) is traded on NASDAQ Exchange in USA. It is located in 770 Lindaro Street, San Rafael, CA, United States, 94901 and employs 3,401 people. Biomarin Pharmaceutical is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 17.24 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Biomarin Pharmaceutical's market, we take the total number of its shares issued and multiply it by Biomarin Pharmaceutical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Biomarin Pharmaceutical conducts business under Biotechnology sector and is part of Health Care industry. The entity has 189.78 M outstanding shares of which 3.06 M shares are currently shorted by private and institutional investors with about 2.39 trading days to cover.
Biomarin Pharmaceutical currently holds about 1.27 B in cash with 159.26 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.85.
Check Biomarin Pharmaceutical Probability Of Bankruptcy
Ownership AllocationBiomarin Pharmaceutical retains a total of 189.78 Million outstanding shares. The majority of Biomarin Pharmaceutical outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Biomarin Pharmaceutical to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Biomarin Pharmaceutical. Please pay attention to any change in the institutional holdings of Biomarin Pharmaceutical as this could imply that something significant has changed or is about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.
Check Biomarin Ownership Details
Biomarin Stock Price Odds Analysis
Contingent on a normal probability distribution, the odds of Biomarin Pharmaceutical jumping above the current price in 90 days from now is about 27.07%. The Biomarin Pharmaceutical probability density function shows the probability of Biomarin Pharmaceutical stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Biomarin Pharmaceutical has a beta of 0.4514 suggesting as returns on the market go up, Biomarin Pharmaceutical average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Biomarin Pharmaceutical will be expected to be much smaller as well. Additionally, biomarin Pharmaceutical has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Biomarin Pharmaceutical to move above the current price in 90 days from now is about 27.07 (This Biomarin Pharmaceutical probability density function shows the probability of Biomarin Stock to fall within a particular range of prices over 90 days) .
Biomarin Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Biomarin Pharmaceutical that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Biomarin Pharmaceutical's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Biomarin Pharmaceutical's value.| Instituion | Recorded On | Shares | |
| Norges Bank | 2023-12-31 | 3.4 M | |
| Elliott Investment Management L.p. | 2023-12-31 | 3 M | |
| Geode Capital Management, Llc | 2023-12-31 | 2.9 M | |
| Hhg Plc | 2023-12-31 | 2.8 M | |
| Bank Of New York Mellon Corp | 2023-12-31 | 2.6 M | |
| Jpmorgan Chase & Co | 2023-12-31 | 2.4 M | |
| Bank Of America Corp | 2023-12-31 | 2.4 M | |
| Nomura Holdings Inc | 2023-12-31 | 2.1 M | |
| Parnassus Investments, Llc | 2023-12-31 | 1.8 M | |
| Primecap Management Company | 2023-12-31 | 18.4 M | |
| Vanguard Group Inc | 2023-12-31 | 18.1 M |
Biomarin Pharmaceutical Historical Income Statement
Biomarin Pharmaceutical Income Statement is one of the three primary financial statements used for reporting Biomarin's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Biomarin Pharmaceutical revenue and expense. Biomarin Pharmaceutical Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Biomarin Pharmaceutical's EBIT is very stable compared to the past year. As of the 19th of April 2024, Research Development is likely to grow to about 784.1 M, while Selling General Administrative is likely to drop about 246.1 M. View More FundamentalsBiomarin Stock Against Markets
Picking the right benchmark for Biomarin Pharmaceutical stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Biomarin Pharmaceutical stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Biomarin Pharmaceutical is critical whether you are bullish or bearish towards Biomarin Pharmaceutical at a given time. Please also check how Biomarin Pharmaceutical's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Biomarin Pharmaceutical without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Analyst Advice Now
Analyst AdviceAnalyst recommendations and target price estimates broken down by several categories |
| All Next | Launch Module |
Biomarin Pharmaceutical Corporate Directors
Biomarin Pharmaceutical corporate directors refer to members of a Biomarin Pharmaceutical board of directors. The board of directors generally takes responsibility for the Biomarin Pharmaceutical's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Biomarin Pharmaceutical's board members must vote for the resolution. The Biomarin Pharmaceutical board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Elaine Heron | Independent Director | Profile | |
| Dennis Slamon | Director | Profile | |
| Robert Hombach | Independent Director | Profile | |
| Richard Meier | Independent Director | Profile |
How to buy Biomarin Stock?
Before investing in Biomarin Pharmaceutical, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Biomarin Pharmaceutical. To buy Biomarin Pharmaceutical stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Biomarin Pharmaceutical. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Biomarin Pharmaceutical stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Biomarin Pharmaceutical stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Biomarin Pharmaceutical stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Biomarin Pharmaceutical, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Biomarin Stock please use our How to Invest in Biomarin Pharmaceutical guide.
Already Invested in Biomarin Pharmaceutical?
The danger of trading Biomarin Pharmaceutical is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Biomarin Pharmaceutical is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Biomarin Pharmaceutical. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Biomarin Pharmaceutical is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for Biomarin Stock analysis
When running Biomarin Pharmaceutical's price analysis, check to measure Biomarin Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomarin Pharmaceutical is operating at the current time. Most of Biomarin Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biomarin Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomarin Pharmaceutical's price. Additionally, you may evaluate how the addition of Biomarin Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Transaction History View history of all your transactions and understand their impact on performance |
Is Biomarin Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.98 | Earnings Share 0.87 | Revenue Per Share 12.88 | Quarterly Revenue Growth 0.202 | Return On Assets 0.0163 |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.